Table 2.

AE37 demographics

	Vaccine (n = 154) n (%)	Control (n = 147) n (%)	p value
Median age (years)	49.0	50.4	0.503
IQR (years)	42.5–57.6	42.7–57.6
T stage			0.706
T0	4 (2.6)	3 (2.0)
Tis/mic	2 (1.3)	3 (2.0)
T1	64 (41.6)	56 (38.1)
T2	57 (37.0)	67 (45.6)
T3	19 (12.3)	14 (9.5)
T4	5 (3.2)	3 (2.0)
Tx	3 (1.9)	1 (0.7)
Nodal status			0.946
Positive	100 (64.9)	96 (65.3)
Negative	54 (35.1)	51 (34.7)
Histology			0.486
Ductal	135 (87.7)	124 (84.4)
Lobular	10 (6.5)	9 (6.1)
Other	9 (5.8)	14 (9.5)
Grade (differentiation)			0.788
Well	10 (6.5)	8 (5.4)
Moderate	66 (42.9)	59 (40.1)
Poor	78 (50.6)	80 (54.4)
ER/PR status			0.969
Positive	95 (61.7)	91 (61.9)
Negative	59 (38.3)	56 (38.1)
HER2 status			0.443
Positive	77 (50.0)	67 (45.6)
Negative	77 (50.0)	80 (54.4)
HLA-A2 status			0.579
Positive	25 (16.2)	25 (17.0)
Negative	129 (83.8)	121 (82.3)
Surgery			0.370
Lumpectomy	63 (40.9)	48 (32.7)
Mastectomy	84 (54.5)	91 (61.9)
Both	7 (4.5)	7 (4.8)
None	0 (0)	1 (0.7)
Radiation therapy			0.775
Adjuvant	118 (76.6)	110 (74.8)
Neoadjuvant	2 (1.3)	1 (0.7)
None	34 (22.1)	36 (24.5)
Chemotherapy			0.403
Adjuvant	109 (70.8)	97 (66.0)
Neoadjuvant	38 (24.7)	36 (24.5)
Adjuvant and neoadjuvant	2 (1.3)	4 (2.7)
None	5 (3.2)	10 (6.8)
Trastuzumab therapy			0.704
Adjuvant	65 (42.2)	55 (37.4)
Neoadjuvant	5 (3.2)	4 (2.7)
Adjuvant and neoadjuvant	6 (3.9)	4 (2.7)
None	78 (50.6)	84 (57.1)
Endocrine therapy			0.546
Aromatase inhibitor	46 (29.9)	43 (29.3)
Tamoxifen	50 (32.5)	47 (32.0)
Ovarian ablation	1 (0.6)	0 (0)
Other	2 (1.3)	0 (0)
None	55 (35.7)	57 (38.8)